Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

TAK-755A Phase 3b, prospective, open-label, multicenter, single treatment arm, continuation study of the safety and efficacy of TAK-755 (rADAMTS-13, also known as BAX 930/SHP655) in the prophylactic and on-demand treatment of subjects with severe…

Principal Investigator: Twist, Clare J

(LUNGMAP) A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (LungMAP Screening Study)

Principal Investigator: Yau, Edwin H

Flavored Tobacco Product Regulation: Behavioral Economic Demand, Visual Attention, and Flavored Tobacco Product Availability

Principal Investigator: Quisenberry, Amanda J

A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Principal Investigator: Wang, Eunice S

A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tumours

Principal Investigator: Fountzilas, Christos

(ALTE1631) A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Cancer

Principal Investigator: Rokitka, Denise A

A phase 2 trial of chemotherapy, Pembrolizumab and Propranolol in advanced esophageal/gastroesophageal junction adenocarcinoma patients.

Principal Investigator: Mukherjee, Sarbajit

Utilizing Patient Reported Quality of Life to Inform Patient Decision Making In Early Stage Lung Cancer

Principal Investigator: Singh, Anurag K

(APEC1621F) NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)- PHASE 2 SUBPROTOCOL OF ENSARTINIB IN PATIENTS WITH TUMORS HARBORING ALK OR ROS1 GENOMIC ALTERATIONS

Principal Investigator: Twist, Clare J

ACCESS: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies

Principal Investigator: McCarthy, Philip L

A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9 Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies

Principal Investigator: McCarthy, Philip L

A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma

Principal Investigator: Hillengass, Jens

Phase II Multicenter Trial of anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma Patients with Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenance Lenalidomide BMT CTN…

Principal Investigator: Ho, Christine M

(FT576-101) A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

Principal Investigator: Ho, Christine M

NRG-GU010: PARALLEL PHASE III RANDOMIZED TRIALS OF GENOMIC RISK STRATIFIED UNFAVORABLE INTERMEDIATE RISK PROSTATE CANCER: DE-INTENSIFICATION AND INTENSIFICATION CLINICAL
TRIAL EVALUATION (GUIDANCE)

Principal Investigator: Kuettel, Michael R

Phase 2 Trial of Belantamab Mafoditin Consolidation Treatment in Patients with Multiple Myeloma and MRD Positivity after Autologous Stem Cell Transplantation

Principal Investigator: Hillengass, Jens

TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where…

Principal Investigator: George, Saby

(10366) A Phase I/2 Study of M3814 (peposertib) in Combination with Hypofractionated Radiotherapy for the treatment of Locally Advanced Pancreatic Adenocarcinoma

Principal Investigator: Fountzilas, Christos

A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients with Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma

Principal Investigator: Wang, Eunice S

(ACNS1821) A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)

Principal Investigator: Twist, Clare J

S2107 Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer

Principal Investigator: Vadehra, Deepak

A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma

Principal Investigator: Hillengass, Jens

Asciminib as Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase

Principal Investigator: Thompson, J

(AAML1831) A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations

Principal Investigator: Twist, Clare J

A Phase II Randomized Study of Atezolizumab plus Multi-Kinase Inhibitor versus Multi-Kinase Inhibitor Alone in Subjects with Unresectable, Advanced Hepatocellular Carcinoma Who Previously Received Atezolizumab Plus Bevacizumab

Principal Investigator: Iyer, Renuka V